CN104606199B - 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 - Google Patents

3,7-二氨基-10h-吩噻嗪化合物盐及其用途 Download PDF

Info

Publication number
CN104606199B
CN104606199B CN201510002365.2A CN201510002365A CN104606199B CN 104606199 B CN104606199 B CN 104606199B CN 201510002365 A CN201510002365 A CN 201510002365A CN 104606199 B CN104606199 B CN 104606199B
Authority
CN
China
Prior art keywords
compound
disease
pharmaceutically acceptable
acceptable salt
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510002365.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104606199A (zh
Inventor
克劳德.M.维希克
珍妮特.E.里卡德
查尔斯.R.哈林顿
戴维.霍斯利
约翰.M.D.斯托雷
科林.马歇尔
詹姆斯.P.辛克莱
托马斯.C.巴德利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38421429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104606199(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN104606199A publication Critical patent/CN104606199A/zh
Application granted granted Critical
Publication of CN104606199B publication Critical patent/CN104606199B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
CN201510002365.2A 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 Active CN104606199B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78669006P 2006-03-29 2006-03-29
US60/786,690 2006-03-29
PCT/GB2007/001103 WO2007110627A2 (en) 2006-03-29 2007-03-28 3,7-diamino-10h-phenothiazine salts and their use
CN200780020349.XA CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780020349.XA Division CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途

Publications (2)

Publication Number Publication Date
CN104606199A CN104606199A (zh) 2015-05-13
CN104606199B true CN104606199B (zh) 2022-09-13

Family

ID=38421429

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201811196758.1A Active CN109384741B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN201510002365.2A Active CN104606199B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN201410269784.8A Active CN104119294B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN200780020349.XA Active CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途
CN201510002371.8A Active CN104529939B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811196758.1A Active CN109384741B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201410269784.8A Active CN104119294B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN200780020349.XA Active CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途
CN201510002371.8A Active CN104529939B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途

Country Status (18)

Country Link
US (5) US7888350B2 (enExample)
EP (1) EP2013191B3 (enExample)
JP (3) JP5520043B2 (enExample)
KR (1) KR100983301B1 (enExample)
CN (5) CN109384741B (enExample)
AT (1) ATE478058T3 (enExample)
AU (1) AU2007231124B2 (enExample)
CA (1) CA2646163C (enExample)
DE (1) DE602007008550D1 (enExample)
DK (1) DK2013191T6 (enExample)
EA (1) EA014552B1 (enExample)
ES (1) ES2349322T7 (enExample)
HR (1) HRP20100614T4 (enExample)
IL (2) IL194516A (enExample)
MY (1) MY143757A (enExample)
PL (1) PL2013191T6 (enExample)
PT (1) PT2013191E (enExample)
WO (1) WO2007110627A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
CN101460157B (zh) 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
MY143757A (en) 2006-03-29 2011-07-15 Wista Lab Ltd 3,7-diamond-10h-phenothiazine salts and their use
AU2007274057B2 (en) 2006-07-11 2012-12-13 TauRx Therapeutics Management Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
EP2137172A1 (en) * 2007-04-03 2009-12-30 Prosetta Bioconformatics Inc. Phenothiazin derivatives for antiviral treatments
CA2690746C (en) * 2007-06-19 2018-01-02 Wista Laboratories Ltd Phenothizine compounds for treating mild cognitive impairment
FR2920775B1 (fr) * 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations.
SI2954932T1 (sl) * 2007-10-03 2019-01-31 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
CA3039907C (en) 2008-12-10 2022-12-13 Wista Laboratories Ltd. 3,6-disubstituted xanthylium salts
PT2480540T (pt) * 2009-09-24 2018-02-16 Wista Lab Ltd Pentahidrato de cloreto de metiltionínio e respetivas preparação e utilização farmacêutica
KR20180094126A (ko) * 2009-09-24 2018-08-22 위스타 레보레이토리스 리미티드 결정질 메틸티오니늄 클로라이드（메틸렌 블루） 수화물
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US9192611B2 (en) 2010-11-30 2015-11-24 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
SG192666A1 (en) * 2011-02-11 2013-09-30 Wista Lab Ltd Phenothiazine diaminium salts and their use
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
GB201512678D0 (en) 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) * 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
EP3487505B1 (en) 2016-07-25 2023-05-03 WisTa Laboratories Ltd. Administration and dosage of diaminophenothiazines
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) * 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN107253936B (zh) * 2017-06-23 2021-07-23 复旦大学 一类可用于次氯酸检测的荧光探针及其制备方法和应用
CN108129418A (zh) * 2017-12-22 2018-06-08 郑州大学 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用
EP4364801B1 (en) 2018-07-26 2025-11-12 TauRx Therapeutics Management Ltd. Optimised dosage of diaminophenothiazines in populations
US20210193322A1 (en) 2018-09-05 2021-06-24 Genting Taurx Diagnostic Centre Sdn Bhd Network methods for neurodegenerative diseases
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
CN115916211A (zh) 2020-05-05 2023-04-04 维斯塔实验室有限公司 用于治疗低氧血症的甲基硫堇鎓化合物
US20230165875A1 (en) 2020-05-05 2023-06-01 Wista Laboratories Ltd. Methylthioninium compounds for use in the treatment of covid-19
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
DE102020212508A1 (de) 2020-10-02 2022-04-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
AU2023346900A1 (en) 2022-09-21 2025-04-10 TauRx Therapeutics Management Ltd Novel formulations and vehicles
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease
CN117447421A (zh) * 2023-10-30 2024-01-26 上海沃凯生物技术有限公司 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095011A (en) * 1989-03-06 1992-03-10 Bristol-Myers Company Lyophilized cefepime dihydrochloride for parenteral use
CN1496404A (zh) * 2001-01-15 2004-05-12 ����˹���ѧ���»� 与神经变性疾病中蛋白聚集相关的物质和方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (enExample) 1957-07-17
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
JPS52105931A (en) * 1976-03-02 1977-09-06 Mita Industrial Co Ltd New leuco coloring matters and process for manufacture thereof
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
US5220009A (en) 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
WO1998031219A1 (en) 1997-01-21 1998-07-23 The American National Red Cross Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
EP1687286A1 (en) 2003-11-28 2006-08-09 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
SI2322517T1 (sl) 2004-09-23 2019-06-28 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
US20070116757A1 (en) 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
MY143757A (en) 2006-03-29 2011-07-15 Wista Lab Ltd 3,7-diamond-10h-phenothiazine salts and their use
CN101460157B (zh) 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
DK2001556T3 (da) 2006-03-29 2014-11-10 Wista Lab Ltd Thioninium-forbindelser og anvendelse deraf
AU2007274057B2 (en) 2006-07-11 2012-12-13 TauRx Therapeutics Management Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
CA2690746C (en) 2007-06-19 2018-01-02 Wista Laboratories Ltd Phenothizine compounds for treating mild cognitive impairment
SI2954932T1 (sl) 2007-10-03 2019-01-31 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
SG192666A1 (en) 2011-02-11 2013-09-30 Wista Lab Ltd Phenothiazine diaminium salts and their use
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP7317787B2 (ja) 2020-10-19 2023-07-31 トヨタ自動車株式会社 排ガス浄化装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095011A (en) * 1989-03-06 1992-03-10 Bristol-Myers Company Lyophilized cefepime dihydrochloride for parenteral use
CN1496404A (zh) * 2001-01-15 2004-05-12 ����˹���ѧ���»� 与神经变性疾病中蛋白聚集相关的物质和方法

Also Published As

Publication number Publication date
IL231890A0 (en) 2014-05-28
US20220152038A1 (en) 2022-05-19
KR100983301B1 (ko) 2010-09-20
JP5814957B2 (ja) 2015-11-17
WO2007110627A3 (en) 2007-11-22
CN104529939A (zh) 2015-04-22
US20250325557A1 (en) 2025-10-23
IL194516A (en) 2015-02-26
CN101460472B (zh) 2015-06-17
IL231890A (en) 2016-10-31
MY143757A (en) 2011-07-15
ATE478058T3 (de) 2010-09-15
CN104606199A (zh) 2015-05-13
US20240245700A1 (en) 2024-07-25
CN104119294B (zh) 2018-10-30
CN109384741B (zh) 2023-01-06
IL194516A0 (en) 2009-08-03
AU2007231124B2 (en) 2013-02-21
CN101460472A (zh) 2009-06-17
EA200870384A1 (ru) 2009-04-28
JP2013121985A (ja) 2013-06-20
HK1209417A1 (en) 2016-04-01
JP2014055165A (ja) 2014-03-27
CA2646163C (en) 2011-03-15
CA2646163F (en) 2007-10-04
JP5520043B2 (ja) 2014-06-11
WO2007110627A2 (en) 2007-10-04
US12324810B2 (en) 2025-06-10
US11951110B2 (en) 2024-04-09
PL2013191T6 (pl) 2019-07-31
DE602007008550D1 (de) 2010-09-30
HRP20100614T4 (hr) 2019-08-09
CN109384741A (zh) 2019-02-26
ES2349322T7 (es) 2019-10-17
JP2009531403A (ja) 2009-09-03
HK1210047A1 (en) 2016-04-15
PL2013191T3 (pl) 2011-02-28
ES2349322T3 (es) 2010-12-29
HK1199444A1 (en) 2015-07-03
US11344558B2 (en) 2022-05-31
CA2646163A1 (en) 2007-10-04
AU2007231124A1 (en) 2007-10-04
EP2013191B3 (en) 2019-02-27
DK2013191T6 (en) 2019-04-23
EP2013191A2 (en) 2009-01-14
US7888350B2 (en) 2011-02-15
CN104529939B (zh) 2019-05-07
KR20080110879A (ko) 2008-12-19
DK2013191T3 (da) 2010-11-22
HRP20100614T1 (hr) 2010-12-31
HK1126480A1 (en) 2009-09-04
PT2013191E (pt) 2010-10-29
US20160051559A1 (en) 2016-02-25
CN104119294A (zh) 2014-10-29
US20090054419A1 (en) 2009-02-26
EA014552B1 (ru) 2010-12-30
EP2013191B1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
CN104606199B (zh) 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
US9174954B2 (en) 3,7-diamino-10H-phenothiazine salts and their use
AU2013200732B2 (en) 3,7-diamino-10H-phenothiazine salts and their use
HK1261726A1 (en) 3,7-diamino-10h-phenothiazine salts and their use
HK1261726B (en) 3,7-diamino-10h-phenothiazine salts and their use
HK1199444B (zh) 3，7-二氨基-10h-吩噻嗪化合物的制备方法
HK1209417B (zh) 3，7-二氨基-10h-吩噻嗪化合物盐及其用途
HK1210047B (en) 3,7-diamino-10h-phenothiazine salts and their use
HK1126480B (en) 3, 7-diamino-10h-phenothiazine salts and their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210047

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment